31st Jan 2014 07:00
Skyepharma PLC Trading Update
LONDON, UK, 31 January 2014 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, today publishes an update as it enters its closed period ahead of its preliminary results announcement for the year ended 31 December 2013, scheduled for 27 March 2014.
Although a number of items need to be finalised in the upcoming accounts closing process, including receipt of royalty statements for the fourth quarter, the Company expects to report full year 2013 revenue and operating profit materially ahead of market expectations.
-Ends-
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 207 881 0524 |
| |
FTI Consulting | |
Julia Phillips/Stephanie Cuthbert/Natalie Garland-Collins | +44 207 831 3113 |
N+1 Singer | |
Shaun Dobson | +44 207 496 3000 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 15 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L